<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783194</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 47/2020/2021</org_study_id>
    <nct_id>NCT04783194</nct_id>
  </id_info>
  <brief_title>Dexamethasone Plus Bupivacaine Versus Bupivacaine in Bilateral Trans-incisional Paravertebral Block in Lumbar Spine Surgeries .</brief_title>
  <official_title>Dexamethasone Plus Bupivacaine Versus Bupivacaine in Bilateral Trans-incisional Paravertebral Block in Lumbar Spine Surgeries, a Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare addition of dexamethasone to bupivacaine versus&#xD;
      bupivacaine alone for trans-incisional bilateral paravertebral block for postoperative&#xD;
      analgesia in elective lumbar spine surgeries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First time to analgesic requirement</measure>
    <time_frame>1st 24 hour</time_frame>
    <description>After extubation, an IV PCA system will be connected to the patient (Accufuser PlusÂ® 100 mL: Woo Young Medical Co, Korea). PCA will be prepared with 60 mL of normal saline containing 60 mg of morphine, and the system will be programmed to give a 0.5 mL bolus dose with a lockout interval of 8 min. basal rate will not be present. PCA will be discontinued at 24 h after surgery, and at that time, oral analgesics begin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption .</measure>
    <time_frame>1st 24 hour</time_frame>
    <description>Total opioid consumption in the first 24 h postoperatively .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS)</measure>
    <time_frame>1st 24 hours postoperatively</time_frame>
    <description>Pain scores will be evaluated by a blinded observer anesthesiologist at the time of arrival in the PACU and 10, 20, and 30 min and 1, 2, 4, 6, 12, and 24 h thereafter using a visual analog scale (VAS) (ranging from0-10 cm: where 0 = no pain, 10 = worst pain). The patients Will be instructed about the usage of the PCA system and the VAS preoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone + bupivacaine in bilateral TiPVB in lumbar spine surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine in bilateral TiPVB in lumbar spine surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone+ Bupivacaine</intervention_name>
    <description>Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.</description>
    <arm_group_label>Dexamethasone + bupivacaine in bilateral TiPVB in lumbar spine surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.</description>
    <arm_group_label>Bupivacaine in bilateral TiPVB in lumbar spine surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  physical status American Society of Anesthesiologists (ASA) I or II.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refuse to participate have a body mass index (BMI) &gt;30 kg/m2 ASA physical status &gt;II&#xD;
             have major illnesses (e.g., cardiac, respiratory, renal, hepatic or neurological)&#xD;
             coagulation abnormalities infection at the injection site tumor in the paravertebral&#xD;
             space sepsis Severe chest deformity or scoliosis, due to the possibility of injection&#xD;
             into the meninges an allergy or contraindications to the drugs used in the study&#xD;
             uncontrolled diabetes patients with active gastric ulceration a history of drug&#xD;
             addiction or alcohol abuse a psychiatric illness mental retardation interfering with&#xD;
             the evaluation of pain scores.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Amin Mohammed Alansary Amin Ahmed Helwa</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

